Skip to main
MYGN

Myriad Genetics (MYGN) Stock Forecast & Price Target

Myriad Genetics (MYGN) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 80%
Sell 20%
Strong Sell 0%

Bulls say

Myriad Genetics is facing challenges in its reproductive health segment, including volume declines and market share loss to competitors, as well as price compression in its hereditary cancer segment. The company's prenatal revenue declined 16% in 2Q26 and management cited ongoing volume challenges as a primary factor. However, the company is looking towards a material growth acceleration in the second half of 2026, driven by strong trends in its hereditary cancer segment and new product launches. Ultimately, the factors that are material to Myriad Genetics's success may change over time, and risks to the upside may include incremental reimbursement and market adoption of existing and new products.

Bears say

Myriad Genetics is facing significant risks to achieving their financial targets due to potential divestitures or asset sales, slower than expected volume recovery in prenatal testing, and ongoing challenges with payer denial and collection issues. Additionally, the company's low valuation does not guarantee a takeout floor and potential buyers may wait for further revenue decreases or margin deterioration before committing capital, putting further pressure on the company's financial performance. These risks are compounded by a changing segment reporting structure and potential challenges with market acceptance of Myriad's new products, such as Precise MRD and GeneSight. Finally, the Medical and Life Science Tools sector as a whole may face challenges such as reduced funding and purchasing from healthcare customers, increased regulatory hurdles, and general economic challenges.

Myriad Genetics (MYGN) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 80% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myriad Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myriad Genetics (MYGN) Forecast

Analysts have given Myriad Genetics (MYGN) a Hold based on their latest research and market trends.

According to 5 analysts, Myriad Genetics (MYGN) has a Hold consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myriad Genetics (MYGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.